Switzerland · Delayed Price · Currency is CHF Exscientia Statistics
Total Valuation
BioVersys AG has a market cap or net worth of CHF 198.00 million. The enterprise value is 182.34 million.
| Market Cap | 198.00M |
| Enterprise Value | 182.34M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
BioVersys AG has 5.82 million shares outstanding.
| Current Share Class | 5.82M |
| Shares Outstanding | 5.82M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 4.33% |
| Float | 4.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 163.23 |
| PB Ratio | 18.54 |
| P/TBV Ratio | 18.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.74 |
| EV / Sales | 150.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -11.68 |
Financial Position
The company has a current ratio of 3.56, with a Debt / Equity ratio of 1.59.
| Current Ratio | 3.56 |
| Quick Ratio | 3.51 |
| Debt / Equity | 1.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.09 |
| Interest Coverage | -18.20 |
Financial Efficiency
Return on equity (ROE) is -194.40% and return on invested capital (ROIC) is -44.89%.
| Return on Equity (ROE) | -194.40% |
| Return on Assets (ROA) | -33.87% |
| Return on Invested Capital (ROIC) | -44.89% |
| Return on Capital Employed (ROCE) | -74.08% |
| Revenue Per Employee | 44,926 |
| Profits Per Employee | -693,296 |
| Employee Count | 27 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 34.99 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 45.27 |
| Average Volume (20 Days) | 1,508 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioVersys AG had revenue of CHF 1.21 million and -18.72 million in losses. Loss per share was -5.62.
| Revenue | 1.21M |
| Gross Profit | 1.21M |
| Operating Income | -18.73M |
| Pretax Income | -18.72M |
| Net Income | -18.72M |
| EBITDA | -18.67M |
| EBIT | -18.73M |
| Loss Per Share | -5.62 |
Balance Sheet
The company has 32.62 million in cash and 16.97 million in debt, giving a net cash position of 15.65 million or 2.69 per share.
| Cash & Cash Equivalents | 32.62M |
| Total Debt | 16.97M |
| Net Cash | 15.65M |
| Net Cash Per Share | 2.69 |
| Equity (Book Value) | 10.68M |
| Book Value Per Share | 32.50 |
| Working Capital | 24.73M |
Cash Flow
In the last 12 months, operating cash flow was -15.57 million and capital expenditures -38,000, giving a free cash flow of -15.61 million.
| Operating Cash Flow | -15.57M |
| Capital Expenditures | -38,000 |
| Free Cash Flow | -15.61M |
| FCF Per Share | -2.68 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,544.11% |
| Pretax Margin | -1,543.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioVersys AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -9.45% |
| FCF Yield | -7.88% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioVersys AG has an Altman Z-Score of -4.1 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.1 |
| Piotroski F-Score | 1 |